Literature DB >> 20357287

Chemoprevention of prostate cancer.

Patrick C Walsh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20357287     DOI： 10.1056/NEJMe1001045

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  23 in total

Review 1.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

2.  Intraethnic variation in steroid-5-alpha-reductase polymorphismsin prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment.

Authors:  Luis Alberto Henríquez-Hernández; Almudena Valenciano; Palmira Foro-Arnalot; María Jesús Álvarez-Cubero; José Manuel Cozar; José Francisco Suárez-Novo; Manel Castells-Esteve; Pablo Fernández-Gonzalo; Belén De-Paula-Carranza; Montse Ferrer; Ferrán Guedea; Gemma Sancho-Pardo; Jordi Craven-Bartle; María José Ortiz-Gordillo; Patricia Cabrera-Roldán; Estefanía Herrera-Ramos; Carlos Rodríguez-Gallego; Pedro C Lara
Journal:  J Genet       Date:  2015-06       Impact factor: 1.166

3.  Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?

Authors:  Richard M Hoffman; Richard G Roberts; Michael J Barry
Journal:  J Gen Intern Med       Date:  2011-01-11       Impact factor: 5.128

4.  Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells.

Authors:  Serge Ginzburg; Konstantin V Golovine; Petr B Makhov; Robert G Uzzo; Alexander Kutikov; Vladimir M Kolenko
Journal:  Prostate       Date:  2013-10-22       Impact factor: 4.104

5.  5α-reductase type 3 enzyme in benign and malignant prostate.

Authors:  Mark A Titus; Yun Li; Olga G Kozyreva; Varun Maher; Alejandro Godoy; Gary J Smith; James L Mohler
Journal:  Prostate       Date:  2013-10-22       Impact factor: 4.104

6.  5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression.

Authors:  Alejandro Godoy; Elzbieta Kawinski; Yun Li; Daizo Oka; Borislav Alexiev; Faris Azzouni; Mark A Titus; James L Mohler
Journal:  Prostate       Date:  2010-12-28       Impact factor: 4.104

7.  Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.

Authors:  Reith R Sarkar; J Kellog Parsons; Alex K Bryant; Stephen T Ryan; Andrew K Kader; Rana R McKay; Anthony V D'Amico; Paul L Nguyen; Benjamin J Hulley; John P Einck; Arno J Mundt; Christopher J Kane; James D Murphy; Brent S Rose
Journal:  JAMA Intern Med       Date:  2019-06-01       Impact factor: 21.873

8.  Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

Authors:  Shidong Jia; Xueliang Gao; Sang Hyun Lee; Sauveur-Michel Maira; Xiaoqiu Wu; Edward C Stack; Sabina Signoretti; Massimo Loda; Jean J Zhao; Thomas M Roberts
Journal:  Cancer Discov       Date:  2012-12-20       Impact factor: 39.397

Review 9.  Future directions in cancer prevention.

Authors:  Asad Umar; Barbara K Dunn; Peter Greenwald
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

Review 10.  An introduction to acinar pressures in BPH and prostate cancer.

Authors:  Panikar Wadhera
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.